For primary endpoint assessment we calculated the percentage of HER2 positive and Triple Negative patients who underwent neoadjuvant treatment in the past 5 years in each site. For this aim all patients with early breast cancer diagnosis who underwent neoadjuvant treatment during the study time, ranging from 01/01/2016 to 01/01/2021, will be included if they had:
Histological diagnosis of infiltrating breast cancer performed by breast and/or axillary nodes biopsy;
Age ≥ 18 years at the time of disease onset;
Absence of secondary lesions, i.e. initial disease stage I, II or III;
Known status of ER, PgR, HER-2 and Ki67.
You may not be if
Documented distant disease at onset diagnosis or within 3 months from breast surgery;
Prior neoadjuvant hormonal treatment exposure;
Prior diagnosis of primary breast cancer or second primitive tumour starting from different organ
Clareo Health | EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
